Advertisement
MTD vs TMO
Which Stock Would AI Choose? Mettler-Toledo International (MTD) vs. Thermo Fisher Scientific (TMO) Stock Comparison
Key Takeaways
- MTD reported first-quarter 2026 sales of $947.1 million, up 7% year-over-year, with adjusted EPS beating estimates.
- TMO maintains broader exposure across life sciences, diagnostics, and applied markets, providing diversified revenue streams compared to MTD’s precision instruments focus.
- Recent market activity shows MTD trading near $1,310 with year-to-date returns lagging broader indices, while TMO exhibits steadier positioning in the healthcare equipment sector.
- Both companies operate in scientific instrumentation and laboratory solutions, yet TMO benefits from larger scale and recurring revenue from consumables.
- Upcoming second-quarter results for MTD on July 30, 2026, represent a near-term catalyst that could influence relative momentum.
- Sector sentiment remains influenced by research and development spending trends, with both stocks sensitive to macroeconomic factors affecting capital equipment purchases.
Introduction
Investors and traders seeking exposure to the scientific instrumentation and laboratory products sector often evaluate MTD and TMO as complementary yet distinct opportunities. Mettler-Toledo International Inc. specializes in precision weighing and analytical instruments, while Thermo Fisher Scientific Inc. offers a wider portfolio spanning research tools, diagnostics, and biopharma services. This comparison highlights differences in business models, recent performance trends, and market positioning that matter to portfolio managers balancing growth potential against stability in a capital-intensive industry.
MTD Overview and Recent Performance
Mettler-Toledo International Inc. provides precision instruments and services for laboratory and industrial applications. In recent weeks, the stock has traded around $1,310 following first-quarter 2026 results that showed sales growth of 7% to $947.1 million and an adjusted earnings per share beat. Year-to-date performance reflects a decline of approximately 6%, underperforming the S&P 500 amid broader market conditions and concerns over organic growth rates. Upcoming second-quarter earnings scheduled for July 30, 2026, serve as a focal point for sentiment, with analysts monitoring order trends in research and manufacturing end markets.
TMO Overview and Recent Performance
Thermo Fisher Scientific Inc. delivers a comprehensive range of scientific instruments, reagents, and services to pharmaceutical, academic, and clinical laboratories. In recent market activity, the company has demonstrated resilience through its diversified revenue base, including recurring consumables sales that provide visibility compared to pure equipment providers. Relative performance has remained more aligned with healthcare sector benchmarks, supported by steady demand in bioprocessing and diagnostics. Market participants continue to assess capital spending patterns and integration progress from prior acquisitions as key variables influencing near-term results.
Trending AI Robots
Tickeron’s Trending AI Robots page curates top-performing AI trading bots from a library of hundreds that collectively trade thousands of tickers. Only those demonstrating the strongest alignment with prevailing market conditions and statistical robustness earn placement in this section. Available bots span diverse trading styles, strategies, timeframes, and performance metrics, allowing users to review ranges of historical returns, win rates, and drawdowns across multiple instruments. This resource helps market participants explore data-driven approaches tailored to specific equities such as those in scientific instrumentation.
Head-to-Head Comparison
MTD operates with a narrower focus on high-precision measurement solutions, resulting in higher margins but greater sensitivity to cyclical capital expenditure by customers. In contrast, TMO benefits from scale and a mix of instruments plus high-margin consumables that support more predictable cash flows. Recent momentum favors TMO for stability, while MTD offers potential upside tied to earnings visibility. Risk factors include supply-chain dependencies for both, though TMO’s larger footprint provides geographic diversification. Sector exposure overlaps in life sciences, yet sentiment shifts often reflect differing end-market exposures to pharmaceutical research versus industrial applications.
Tickeron AI Verdict
Based on observable trend consistency and relative positioning, Tickeron’s AI models currently assign a modestly higher probability of favorable near-term characteristics to TMO due to its broader revenue stability and sector resilience. MTD presents a catalyst-driven profile ahead of its earnings release that could alter relative assessments depending on results and forward guidance.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MTD is a StrongBuy and TMO is a Hold.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
MTD’s FA Score shows that 1 FA rating(s) are green whileTMO’s FA Score has 1 green FA rating(s).
- MTD’s FA Score: 1 green, 4 red.
- TMO’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
MTD’s TA Score shows that 5 TA indicator(s) are bullish while TMO’s TA Score has 6 bullish TA indicator(s).
- MTD’s TA Score: 5 bullish, 5 bearish.
- TMO’s TA Score: 6 bullish, 4 bearish.
Price Growth
MTD (@Medical Specialties) experienced а +4.91% price change this week, while TMO (@Medical Specialties) price change was +6.33% for the same time period.
The average weekly price growth across all stocks in the @Medical Specialties industry was +0.13%. For the same industry, the average monthly price growth was -0.98%, and the average quarterly price growth was +2.98%.
Reported Earning Dates
MTD is expected to report earnings on Jul 30, 2026.
TMO is expected to report earnings on Oct 28, 2026.
Industries' Descriptions
@Medical Specialties (+0.13% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
| MTD | TMO | MTD / TMO | |
| Capitalization | 27B | 208B | 13% |
| EBITDA | 1.25B | 11.7B | 11% |
| Gain YTD | -4.153 | -3.245 | 128% |
| P/E Ratio | 31.39 | 30.11 | 104% |
| Revenue | 4.09B | 45.2B | 9% |
| Total Cash | 60.6M | 1.12B | 5% |
| Total Debt | 2.23B | 43.2B | 5% |
MTD | TMO | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 46 | 37 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 99 Overvalued | 12 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 80 | |
SMR RATING 1..100 | 2 | 62 | |
PRICE GROWTH RATING 1..100 | 48 | 42 | |
P/E GROWTH RATING 1..100 | 51 | 37 | |
SEASONALITY SCORE 1..100 | 50 | 65 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
TMO's Valuation (12) in the Medical Specialties industry is significantly better than the same rating for MTD (99). This means that TMO’s stock grew significantly faster than MTD’s over the last 12 months.
TMO's Profit vs Risk Rating (80) in the Medical Specialties industry is in the same range as MTD (100). This means that TMO’s stock grew similarly to MTD’s over the last 12 months.
MTD's SMR Rating (2) in the Medical Specialties industry is somewhat better than the same rating for TMO (62). This means that MTD’s stock grew somewhat faster than TMO’s over the last 12 months.
TMO's Price Growth Rating (42) in the Medical Specialties industry is in the same range as MTD (48). This means that TMO’s stock grew similarly to MTD’s over the last 12 months.
TMO's P/E Growth Rating (37) in the Medical Specialties industry is in the same range as MTD (51). This means that TMO’s stock grew similarly to MTD’s over the last 12 months.
| MTD | TMO | |
|---|---|---|
| RSI ODDS (%) | 4 days ago 67% | 4 days ago 61% |
| Stochastic ODDS (%) | 4 days ago 65% | 4 days ago 60% |
| Momentum ODDS (%) | 4 days ago 66% | 4 days ago 59% |
| MACD ODDS (%) | 4 days ago 67% | 4 days ago 66% |
| TrendWeek ODDS (%) | 4 days ago 61% | 4 days ago 61% |
| TrendMonth ODDS (%) | 4 days ago 58% | 4 days ago 61% |
| Advances ODDS (%) | 12 days ago 60% | 5 days ago 61% |
| Declines ODDS (%) | 8 days ago 66% | 7 days ago 63% |
| BollingerBands ODDS (%) | 4 days ago 86% | 4 days ago 63% |
| Aroon ODDS (%) | 4 days ago 53% | 4 days ago 59% |
Advertisement
MTD and
Correlation & Price change
A.I.dvisor indicates that over the last year, MTD has been closely correlated with A. These tickers have moved in lockstep 71% of the time. This A.I.-generated data suggests there is a high statistical probability that if MTD jumps, then A could also see price increases.
| Ticker / NAME | Correlation To MTD | 1D Price Change % | ||
|---|---|---|---|---|
| MTD | 100% | +0.69% | ||
| A - MTD | 71% Closely correlated | -0.49% | ||
| TMO - MTD | 67% Closely correlated | -1.54% | ||
| BRKR - MTD | 67% Closely correlated | -0.66% | ||
| AZTA - MTD | 61% Loosely correlated | +0.55% | ||
| RVTY - MTD | 58% Loosely correlated | -2.17% | ||
More | ||||